JAMA Medical News

What the Latest Research Says About Paxlovid; People Are Using Potentially Dangerous "Trip-Killers" to Counter Psychedelics; Social Media Affects Youth Mental Health—Here's What Could Help Related Content: Paxlovid Is Effective but Underused—Here's What the Latest Research Says About Rebound and More Study Finds Hundreds of Reddit Posts on "Trip-Killers" for Psychedelic Drugs Social Media Industry Standards Needed to Protect Adolescent Mental Health, Says National Academies

Experts discuss racial bias in clinical algorithms, including efforts to remove race calculations. The podcast also covers the reliability of electronic health records and the inclusion of social determinants of health. Updates on the Omicron variant, vaccine effectiveness, and the impact of non-pharmaceutical interventions are included.

Atul Butte, Director of the Bakar Computational Health Sciences Institute at UCSF, discusses using AI to democratize healthcare, utilizing large datasets for comparative effectiveness research, ensuring patient data privacy, improving healthcare outcomes through data analysis, and addressing the risks of AI language model extrapolation.

Arvind Narayanan, professor of computer science at Princeton, joins JAMA's Editor in Chief Kirsten Bibbins-Domingo to explore AI fairness, transparency, and accountability in healthcare. They discuss the racial bias in hospital algorithms, limitations of AI technologies, and the need for constant monitoring. The podcast also highlights the challenges of data availability, privacy concerns, and the potential of generative AI for self-diagnosis.

The Next Generation of COVID-19 Vaccines May Be Inhaled; Does Paxlovid Prevent Long COVID? Apply to the Morris Fishbein Fellowship in Medical Editing. Related Content: Up the Nose and Down the Windpipe May Be the Path to New and Improved COVID-19 Vaccines Studies Investigate Whether Antivirals Like Paxlovid May Prevent Long COVID The Morris Fishbein Fellowship in Medical Editing

Alondra Nelson, Professor at the Institute for Advanced Study, discusses the equitable regulation of AI in disease diagnosis, the implications of the Biden administration's executive order on AI, the need for guardrails in AI similar to genetic testing, and aligning AI with societal values in clinical practice.

Dr. John Ayers from UC San Diego discusses the potential of genAI programs like ChatGPT to enhance communication pathways for better patient outcomes. They explore the effectiveness of AI tools in improving patient care, especially in public health communication. The conversation emphasizes the importance of focusing on clinical endpoints and outcomes in healthcare regulation and research studies.

Why Physicians Don't Deprescribe Medicines; What to Know About Wegovy's Rare but Serious Adverse Effects; What to Know About Zepbound, the Newest Antiobesity Drug Related Content: As Semaglutide's Popularity Soars, Rare but Serious Adverse Effects Are Emerging FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management Deciding When It's Better to Deprescribe Medicines Than to Continue Them

JAMA Associate Editor Gregory Marcus, MD, a cardiologist and professor of medicine at the University of California San Francisco, speaks with American Heart Association Scientific Sessions 2023 conference chair Amit Khera, MD, MSc, a professor in the department of internal medicine at UT Southwestern Medical Center and the director of preventive cardiology. Related Content: Highlights From AHA 2023—New Risk Calculator, Semaglutide and CVD, and More

Nigam Shah, Stanford University professor, discusses reshaping medicine with AI. Topics include challenges with Electronic Health Records, training AI models with unbiased data, ethical data contribution, and the impact of technology on healthcare delivery.